Abitbol H F, Carrizo Paez R, Derlis Abate C
Cátedra de Farmacología, Facultad de Ciencia Médicas, Universidad Nacional de Cuyo, Mendoza, Argentina.
Arch Inst Cardiol Mex. 1988 Mar-Apr;58(2):107-14.
We studied 20 patients with a confirmed diagnosis of Chagas heart disease. Clinical and electrocardiography examinations at baseline documented that all patients had chronic PVC's and that 40% of them also had supraventricular extrasystoles. Also 80% of the patients had RBBB's, 70% had LBBB's and 35% had 1st. degree AV blocks. Flecainide (F) completely suppressed the arrhythmias in 85% of the patients and did partially so in 98% of the patients. Flecainide did not affect sinus node function except in one patient who developed a sinus node atrial block. PR and QRS intervals were prolonged after F but there no 2nd or 3rd degree AV blocks. Flecainide demonstrated to be highly effective with a comfortable margin of safety in the management of these patients with marked alterations of their pace-making and conduction functions.
我们研究了20例确诊为恰加斯心脏病的患者。基线时的临床和心电图检查表明，所有患者均有慢性室性早搏，其中40% 还伴有室上性早搏。此外，80% 的患者有右束支传导阻滞，70% 有左束支传导阻滞，35% 有一度房室传导阻滞。氟卡尼（F）使85% 的患者心律失常完全得到抑制，98% 的患者心律失常部分得到抑制。除1例发生窦房结心房阻滞的患者外，氟卡尼不影响窦房结功能。使用氟卡尼后PR和QRS间期延长，但未出现二度或三度房室传导阻滞。在治疗这些起搏和传导功能明显改变的患者时，氟卡尼显示出高效且安全性良好。
